Synopsis

Source of validity: Scientific
Rating (out of 5): 3

L12-myoviridae refers to a type of bacteriophage—a virus that infects and destroys bacteria. The use of bacteriophages (phage therapy) to treat bacterial infections has a long history, particularly in Eastern Europe and the former Soviet Union, but in recent years, scientific interest in phage therapy has increased globally due to rising antibiotic resistance. L12-myoviridae phages are part of the Myoviridae family, which are known for their contractile tails and effectiveness against a variety of bacterial pathogens.

There is moderate scientific evidence (rated 3/5) supporting the use of L12-myoviridae and similar phages to treat bacterial infections. Preclinical studies and some clinical case reports have demonstrated that specific phages can effectively target and lyse pathogenic bacteria, including multidrug-resistant strains of Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus. For example, compassionate use cases and small clinical trials have reported success in treating otherwise untreatable infections using bacteriophage preparations. However, large-scale, randomized controlled trials are still limited, and regulatory pathways for phage therapy are still being developed in most countries.

In summary, while there is a growing body of scientific evidence supporting the use of L12-myoviridae phages for bacterial infections, particularly in the context of antibiotic resistance, the field is still emerging, and more robust clinical data are needed. Nevertheless, the scientific rationale for their use is strong, and ongoing research may further validate their therapeutic potential.

More about L12-myoviridae
More about Infection (bacterial)

Other ingredients used for Infection (bacterial)

Other health conditions supported by L12-myoviridae

Products containing L12-myoviridae